Lucid Diagnostics Inc. Q4 FY2025 earnings call

Key highlights include: EsoGuard test volume in Q4 was 3,664 (exceeding target), revenue up 24%; awarded VA contract for EsoGuard; announced positive data from large real-world study of esophageal precancer testing; progress on reimbursement with payers like UnitedHealthcare, Cigna, Anthem; work on EHR integration; reallocation of commercial resources for VA and Medicare; appointment of VA National Director.

EsoGuard test volume in Q4 was 3,664, exceeding the target range of ~2,500 - 3,000 tests per quarter. Revenue was $1,500,000, a 24% increase from 2025. Revenue contribution % not explicitly stated.

Management anticipates Medicare coverage to be imminent; continues to push forward on VA engagements and commercial payer negotiations; expects to see wins in commercial side over coming quarters as work on reimbursement and VA progresses.

Risks include actual results differing from forward-looking statements due to known and unknown risks; delays in Medicare coverage; commercial payers requiring cost-effectiveness data; logistical delays in LCD publication.

Q: About Q4 volume increase and VA contribution, A: 800 increase not directly from VA, but team productivity and transition to Medicare/VA; Q: UnitedHealthcare coverage, A: Viewed as de facto coverage, initiated credentialing; Q: Medicare mix and LBM, A: Medicare claims up 28% q-o-q, LBM first positive coverage upcoming; Q: VA sales coverage and OpEx, A: National and local team engagement, OpEx level to continue; Q: Testing volume and VA market, A: Mix of factors, VA serves 9M veterans with high risk of GERD.